- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06154252
Open-label studie för att utvärdera säkerheten och effektiviteten av CABA-201 hos personer med aktiv idiopatisk inflammatorisk myopati
En öppen fas 1/2-studie för att utvärdera säkerheten och effektiviteten av autologa CD19-specifika chimära antigenreceptor-T-celler (CABA-201) hos patienter med aktiv idiopatisk inflammatorisk myopati
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Cabaletta Bio
- Telefonnummer: 4444 267-759-3100
- E-post: clinicaltrials@cabalettabio.com
Studieorter
-
-
California
-
Orange, California, Förenta staterna, 92868
- Rekrytering
- University of California Irvine - Accepting Adult Patients
-
Huvudutredare:
- Tahseen Mozaffar, MD
-
Kontakt:
- Alpha Clinic
- Telefonnummer: 949-824-3990
- E-post: alphaclinic@uci.edu
-
San Francisco, California, Förenta staterna, 94158
- Rekrytering
- University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Zilan Zheng
- Telefonnummer: 415-353-1301
- E-post: Zilan.Zheng@ucsf.edu
-
Huvudutredare:
- Susan Kim, MD, MMSc
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80046
- Rekrytering
- Children's Hospital Colorado - Accepting Juvenile Patients
-
Huvudutredare:
- Dr. Kentaro Yomogida, MD
-
Kontakt:
- Callie Strini - Primary Clinical Research Coordinator
- Telefonnummer: 720-777-9845
- E-post: callie.strini@childrenscolorado.org
-
-
Florida
-
Jacksonville, Florida, Förenta staterna, 32224
- Rekrytering
- Mayo Clinic Florida - Accepting Adult Patients
-
Kontakt:
- Gabrielle Pariseau
- Telefonnummer: 904-953-5549
- E-post: pariseau.gabrielle@mayo.edu
-
St. Petersburg, Florida, Förenta staterna, 33701
- Rekrytering
- Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
-
Huvudutredare:
- Natalie Booth, DO
-
Kontakt:
- Laura Escobar
- Telefonnummer: 727-767-2946
- E-post: llabarr2@jh.edu
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30032
- Rekrytering
- Emory University - Accepting Adult Patients
-
Kontakt:
- John Varghese
- E-post: john.varghese@emory.edu
-
Huvudutredare:
- Prateek Chandrashekar Gandiga, MD, FACP
-
Atlanta, Georgia, Förenta staterna, 30029
- Rekrytering
- Children's Healthcare of Atlanta - Accepting Juvenile Patients
-
Huvudutredare:
- Shanmuganathan Chandrakasan, MD
-
Kontakt:
- Judson Russell
- Telefonnummer: 404-785-7263
- E-post: Judson.russell@choa.org
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Rekrytering
- Northwestern Memorial Hospital - Accepting Adult Patients
-
Huvudutredare:
- Dr. George Georges, MD
-
Kontakt:
- Kaitlin King
- Telefonnummer: 312-695-0990
- E-post: autoimmunesct@nm.org
-
Chicago, Illinois, Förenta staterna, 60637
- Rekrytering
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients
-
Huvudutredare:
- Dr. Iazsmin Ventura, MD
-
Kontakt:
- Dr. Iazsmin Ventura, MD - Adult patient contact
- Telefonnummer: 773-702-6619
- E-post: iventura@uchicago.edu; Dequana.jones@bsd.uchicago.edu
-
Underutredare:
- Dr. Cuoghi Edens, MD, FAAP
-
Kontakt:
- Dr. Cuoghi Edens, MD, FAAP - Juvenile patient contact
- E-post: cedens@bsd.uchicago.edu; Sydni.Hill@bsd.uchicago.edu
-
Chicago, Illinois, Förenta staterna, 60611
- Rekrytering
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Tyler Sorensen
- Telefonnummer: 312-277-6828
- E-post: tsorensen@luriechildrens.org
-
Huvudutredare:
- Pooja N. Patel, DO
-
-
Kansas
-
Kansas City, Kansas, Förenta staterna, 66160
- Rekrytering
- University of Kansas Medical Center - Accepting Adult Patients
-
Kontakt:
- Samantha Colgan
- Telefonnummer: 913-945-9938
- E-post: scolgan@kumc.edu
-
-
Maryland
-
Bethesda, Maryland, Förenta staterna, 20892
- Rekrytering
- National Institutes of Health - Accepting Adult and Juvenile Patients
-
Kontakt:
- Julie Thompson
- Telefonnummer: 301-480-3191
- E-post: Julie.thompson@nih.gov
-
Huvudutredare:
- Andrew Mammen, M.D., Ph.D.
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Rekrytering
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
-
Huvudutredare:
- Susan Prockop, MD
-
Kontakt:
- Kyle McBrearty
- Telefonnummer: 617-355-2780
- E-post: kyle.mcbrearty@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48105
- Rekrytering
- University of Michigan - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Abigail Whalen
- Telefonnummer: 734-615-4466
- E-post: abigaiwh@med.umich.edu
-
Huvudutredare:
- Dr. Jennifer Agrusa, MD
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55902
- Rekrytering
- Mayo Clinic - Accepting Adult Patients
-
Kontakt:
- Bridget Neja
- Telefonnummer: 507-266-9150
- E-post: neja.bridget@mayo.edu
-
-
New York
-
New York, New York, Förenta staterna, 10021
- Rekrytering
- Hospital for Special Surgery - Accepting Adult and Juvenile Patients
-
Kontakt:
- Janvi Bhatia
- Telefonnummer: 212-774-2123
- E-post: bhatiaj@hss.edu
-
Huvudutredare:
- David R. Fernandez, MD, PhD
-
New York, New York, Förenta staterna, 10021
- Rekrytering
- Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
-
Huvudutredare:
- Jae Park, MD
-
Kontakt:
- Atifah Osrat
- Telefonnummer: 646-608-2091
- E-post: osrata1@mskcc.org
-
The Bronx, New York, Förenta staterna, 10467
- Rekrytering
- Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Emily Gillies
- Telefonnummer: 718-696-2402
- E-post: egillies@montefiore.org
-
Huvudutredare:
- Dr. Dawn Wahezi, MD, MS
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599
- Rekrytering
- University of North Carolina at Chapel Hill - Accepting Adult Patients
-
Huvudutredare:
- Saira Sheikh, MD
-
Kontakt:
- Leah Luizza
- E-post: leah.luizza@med.unc.edu
-
Durham, North Carolina, Förenta staterna, 27710
- Rekrytering
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients
-
Huvudutredare:
- Kaveh Ardalan, MD, MS
-
Kontakt:
- Lynn Rodgers, MS
- Telefonnummer: 919-668-2953
- E-post: Lynn.rodgers@duke.edu
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97239
- Rekrytering
- Oregon Health & Science University - Accepting Adult Patients
-
Kontakt:
- Katie Lewis
- Telefonnummer: 503-908-9724
- E-post: lewiskat@ohsu.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Rekrytering
- Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- CARTintake@chop.edu
- E-post: CARTintake@chop.edu
-
Huvudutredare:
- Dr. Caitlin Elgarten, MD, MSCE
-
Pittsburgh, Pennsylvania, Förenta staterna, 15261
- Rekrytering
- UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
-
Kontakt:
- Carol Oriss
- E-post: orissca@upmc.edu
-
Huvudutredare:
- Jeremy Tilstra, MD
-
Pittsburgh, Pennsylvania, Förenta staterna, 15224
- Rekrytering
- UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
-
Kontakt:
- Vibha Chauhan, PhD
- Telefonnummer: 412-692-7924
- E-post: Vibha.chauhan@chp.edu
-
Huvudutredare:
- Kathryn Torok, MD
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37232
- Rekrytering
- Vanderbilt University Medical Center - Accepting Adult Patients
-
Kontakt:
- Tofi Soneye
- Telefonnummer: 817-883-4730
- E-post: tofi.soneye@vumc.org
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75390
- Rekrytering
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients
-
Huvudutredare:
- Samuel John, MD
-
Kontakt:
- Dr. Samuel John
- E-post: dtpteam@childrens.com
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- Houston Methodist Hospital - Accepting Adult Patients
-
Kontakt:
- Amelia A. Nounes, MSN, RN, CCRP
- Telefonnummer: 346-356-3639
- E-post: aanounes@houstonmethodist.org
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients
-
Huvudutredare:
- Huifang (Linda) Lu, MD
-
Kontakt:
- Christina Amos Briggs, BSN, RN
- Telefonnummer: 713-563-5076
- E-post: cbamos@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84113
- Rekrytering
- Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
-
Kontakt:
- Morgan Badgley - Research Coordinator
- Telefonnummer: 801-662-4812
- E-post: morgan.badgley@hsc.utah.edu
-
Huvudutredare:
- Aimee Ogden Hersh, MD
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98105
- Rekrytering
- Seattle Children's Research Institute - Accepting Juvenile Patients
-
Kontakt:
- Dr. Susan Shenoi, MD, MS
- Telefonnummer: 206-987-2193
- E-post: susan.shenoi@SeattleChildrens.org
-
Huvudutredare:
- Dr. Susan Shenoi, MD, MS
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Har inte rekryterat ännu
- Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
-
Huvudutredare:
- Sara Sabbagh, DO
-
Kontakt:
- Erin Hammelev - Research Coordinator
- Telefonnummer: 414-337-7064
- E-post: ehammele@mcw.edu
-
-
-
-
-
Roma, Italien, 00165
- Rekrytering
- Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
-
Kontakt:
- Dr. Marco Becilli
- Telefonnummer: +39 0668592739
- E-post: marco.becilli@opbg.net
-
Huvudutredare:
- Professor Franco Locatelli
-
-
-
-
-
London, Storbritannien, WC1N 3BG
- Rekrytering
- University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
-
Kontakt:
- Dr. Pedro Machado, FRCP, PhD
- Telefonnummer: 020 3456 7890
- E-post: uclh.car-ttrials@nhs.net
-
Huvudutredare:
- Dr. Pedro Machado, FRCP, PhD
-
London, Storbritannien, SE5 9RS
- Rekrytering
- Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
-
Kontakt:
- Rheumatology Research Team
- Telefonnummer: 0628 0207 848 0214
- E-post: Kch-tr.CRDresearch@nhs.net
-
Huvudutredare:
- Patrick Gordon, PhD, FRCP, MBBS
-
London, Storbritannien, WC1N 3JH
- Rekrytering
- Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
-
Kontakt:
- Professor Despina Eleftheriou
- Telefonnummer: 020 7405 9200
- E-post: Despina.Eleftheriou@gosh.nhs.uk
-
Huvudutredare:
- Professor Despina Eleftheriou
-
Manchester, Storbritannien, M13 9WL
- Rekrytering
- Manchester Royal Infirmary - Accepting Adult Patients
-
Kontakt:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
- Telefonnummer: 01612765052
- E-post: Eleni.Tholouli@mft.nhs.uk
-
Huvudutredare:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
-
Salford, Storbritannien, M6 8HD
- Rekrytering
- Salford Royal Hospital - Accepting Adult Patients
-
Kontakt:
- Michelle Beswick
- Telefonnummer: 07759 136787
- E-post: Rheumatology.Research@nca.nhs.uk
-
Huvudutredare:
- Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
-
-
-
-
-
Göttingen, Tyskland, 37075
- Har inte rekryterat ännu
- Universitätsmedizin Göttingen - Accepting Adult Patients
-
Kontakt:
- Dr. Jana Zschüntzsch
- E-post: j.zschuentzsch@med.uni-goettingen.de
-
Huvudutredare:
- Dr. Jana Zschüntzsch
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Adult Cohorts
Inclusion Criteria:
- Age ≥18 and ≤75
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Diagnosis of DM, ASyS, or IMNM
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
- Presence of muscle weakness
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Juvenile Cohort
Inclusion Criteria:
- Age ≥6 and ≤17 years at enrollment
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: CABA-201 Phase 1/2
DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM. ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS. IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andra namn:
|
|
Experimentell: CABA-201 Phase 2b - Sub-study 1
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andra namn:
|
|
Experimentell: CABA-201 Phase 2b - Sub-study 2
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Phase 1/2: Incidence and severity of adverse events (AEs)
Tidsram: Up to 28 days after CABA-201 infusion
|
Incidence and severity of AEs |
Up to 28 days after CABA-201 infusion
|
|
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Tidsram: Within 16 weeks
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 16 weeks
|
|
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Tidsram: Within 24 weeks
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 24 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of adverse events and laboratory abnormalities
Tidsram: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Incidence and severity of AEs, including changes in laboratory values and vital signs |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacodynamics (PD)
Tidsram: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of B cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacokinetics (PK)
Tidsram: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of CABA-201-positive T cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Change in disease-related biomarkers of muscle inflammation
Tidsram: Up to 156 weeks (Phase 1/2)
|
Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum |
Up to 156 weeks (Phase 1/2)
|
|
Change in autoantibody-related biomarkers
Tidsram: Up to 156 weeks (Phase 1/2)
|
Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum |
Up to 156 weeks (Phase 1/2)
|
|
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Tidsram: Week 16 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Tidsram: Week 16 (Sub-study 1)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 16 (Sub-study 1)
|
|
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Tidsram: Week 16 (Sub-study 1)
|
≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tidsram: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tidsram: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Tidsram: Week 24 (Sub-study 2)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 24 (Sub-study 2)
|
|
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Tidsram: Week 52 (Sub-study 2)
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 2)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Medical Director, Cabaletta Bio
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Muskuloskeletala sjukdomar
- Sjukdomar i nervsystemet
- Muskelsjukdomar
- Neuromuskulära sjukdomar
- Bindvävssjukdomar
- Immunsystemets sjukdomar
- Hudsjukdomar
- Polymyosit
- Hud- och bindvävssjukdomar
- Autoimmuna sjukdomar
- Dermatomyosit
- Myosit
- Organiska kemikalier
- Kolväten
- Fosforamidsen
- Kväve senapsföreningar
- Senapsföreningar
- Kolväten, halogenerad
- Fosforamider
- Organofosforföreningar
- Cyklofosfamid
- fludarabin
Andra studie-ID-nummer
- CAB-201-002
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .